drugset
drugset / Trial / NCT05780645

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

NCT05780645 ↗

Phase 1 Completed 80 enrolled Alexion Pharmaceuticals, Inc.
RandomizedSequentialOpen-labelTreatment

Summary

The primary objectives of this study are to investigate the relative bioavailability and PK (Pharmacokinetic) profile of 2 ALXN2050 MR (Modified Release) formulations in comparison with the IR (Immediate Release) formulation.

Timeline

Start
2023-03-15
Primary completion
2024-02-26
Completion
2024-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Vemircopan Small molecule — Oral

Indications

No indication recorded.